申请人:PFIZER INC.
公开号:EP0095341A1
公开(公告)日:1983-11-30
A compound of the formula
is a prodrug of 4,4-dioxopenicillanic acid, wherein R is hydrogen or methyl; R R2 and R3 (a) when taken individually are each alkyl containing one to four carbon atoms, or (b) when taken together with the nitrogen to which they are attached form a five- or six-membered saturated monocyclic moiety, an eight-membered saturated bicyclic moiety or a five- or six-membered aromatic cyclic moiety annulated with zero, one or two fused benzene rings, with the proviso that any Ri, R2 or R3 not part of a cyclic moiety is alkyl containing one to four carbon atoms; and X- is a pharmaceutically-acceptable anion. The prodrug can be included with a beta-lactam antibiotic in a pharmaceutical composition which can be employed in the treatment of infection in mammals. The above-described compounds hydrolyze in vivo to 4.4-dioxopenicillanic acid.
式中的化合物
是 4,4-二氧代青霉烷酸的原药,其中 R 是氢或甲基;R R2 和 R3 (a) 单个时均为含 1 至 4 个碳原子的烷基,或 (b) 与所连接的氮一起形成五元或六元饱和单环分子、八元饱和双环分子或环有 0、1 或 2 个融合苯环的五元或六元芳香环分子,但任何不属于环分子的 Ri、R2 或 R3 均为含 1 至 4 个碳原子的烷基;X- 是药学上可接受的阴离子。该原药可与β-内酰胺类抗生素一起加入药物组合物中,用于治疗哺乳动物的感染。上述化合物在体内水解为 4.4-二氧代青霉烷酸。